Comment from JTI LIGGETT LLC
AnonymousOpposeBusiness
Summary: JTI LIGGETT LLC opposes the draft guidance, arguing that it fails to provide a clear, workable pathway for flavored ENDS authorizations and does not adequately account for the illicit market. The company argues that the guidance ignores the role of flavors in adult smoking cessation and lacks transparency regarding how the FDA evaluates flavor-related risks and device access restriction (DAR) technologies.
JTI LIGGETT LLC comments to Docket No. FDA‑2026‑D‑1817, “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk; Draft Guidance for Industry.” See attached file.